• Q-VD-OPh: Potent Pan-Caspase Inhibitor for Apoptosis Researc

  2026-05-16

  Q-VD-OPh is a highly selective, irreversible pan-caspase inhibitor used to dissect apoptotic pathways in vitro and in vivo. It targets multiple caspases at nanomolar potency and enhances cell viability, especially post-cryopreservation. Its utility spans apoptosis research and neurodegenerative disease models.

• Linoleic Acid Drives Tumor Progression in pLELC via PPARα–TF

  2026-05-15

  This study reveals that linoleic acid (LA) promotes tumor progression in primary pulmonary lymphoepithelioma-like carcinoma (pLELC) by upregulating tissue factor (TF) expression through the PPARα pathway. Multiomics profiling and xenograft model validation highlight the central role of the LA–PPARα–TF signaling axis, suggesting TF as a promising therapeutic target for this rare lung cancer.

• PAD4-IN-2 TFA: Precision Inhibition of H3 Citrullination in

  2026-05-15

  PAD4-IN-2 TFA, a meta-phenylboronic acid-modified PAD4 inhibitor, delivers high tumor selectivity and robust inhibition of histone H3 citrullination and NET formation. Unlock advanced immune microenvironment modulation and antitumor efficacy with state-of-the-art workflow guidance and troubleshooting tips tailored for bench scientists.

• N6-Methyl-dATP: Advancing Epigenetics from Mechanism to Clin

  2026-05-14

  This thought-leadership article examines the mechanistic, experimental, and translational dimensions of N6-Methyl-dATP, spotlighting its role as a precision probe for DNA replication fidelity and epigenetic regulation. By integrating emerging insights into the LMO2/LDB1 oncogenic axis in AML, current best practices for workflow optimization, and a comparative landscape analysis, the article delivers strategic guidance for researchers aiming to bridge discovery and clinical innovation. The discussion showcases APExBIO’s N6-Methyl-dATP (SKU B8093) as a next-generation tool, emphasizing its unique methylation profile and translational promise in genomic stability and targeted drug design.

• Cabozantinib (XL184): Advanced Workflows in RCC Signaling Re

  2026-05-14

  Leverage Cabozantinib (XL184) for timescale-dependent phosphoproteomic dissection and antiangiogenic modeling in renal cell carcinoma. This guide details experimental enhancements, troubleshooting, and practical insights directly informed by recent systems-level studies.

• Cefepime (BMY-28142): Neurotoxicity, CNS Models, and Assay P

  2026-05-13

  Explore how Cefepime (BMY-28142) empowers advanced neurotoxicity studies and central nervous system infection models. This in-depth guide reveals best practices, mechanistic insights, and protocol parameters for rigorous research applications.

• 25-Hydroxycholesterol Orchestrates Macrophage Immunometaboli

  2026-05-13

  Xiao et al. (2024) reveal how 25-hydroxycholesterol accumulates in tumor-associated macrophages, activating AMPKα via a lysosomal pathway to drive immunosuppressive polarization and limit antitumor immunity. Their mechanistic insights spotlight CH25H as a metabolic checkpoint, with translational relevance for immunotherapy combinations.

• Q-VD(OMe)-OPh: Precise Caspase Inhibition for Apoptosis Assa

  2026-05-12

  Q-VD(OMe)-OPh redefines apoptosis research with broad-spectrum, non-toxic caspase inhibition and robust reproducibility in both in vitro and in vivo models. Its superior potency and workflow flexibility empower advanced studies in cancer resistance and neuroprotection, outperforming legacy inhibitors.

• Lactate Drives HMGB1 Modification and Exosomal Release in Se

  2026-05-12

  This study reveals that lactate actively promotes both lactylation and acetylation of HMGB1 in macrophages during polymicrobial sepsis, leading to enhanced exosomal release and increased endothelial permeability. These findings highlight lactate-associated pathways as potential therapeutic targets in inflammatory signaling and sepsis intervention.

• Azathramycin A: Precision Tool for Protein Synthesis Inhibit

  2026-05-11

  Explore Azathramycin A, a macrolide antibiotic uniquely suited for probing Mycobacterium tuberculosis protein synthesis inhibition and resistance mechanisms. This article delivers advanced analytical guidance for assay design and resistance modeling.

• Pregnenolone Carbonitrile: PXR Agonist for Hepatic and Water

  2026-05-11

  Pregnenolone Carbonitrile (PCN) extends beyond classic xenobiotic metabolism studies, enabling precise control over hepatic detoxification and water balance pathways. Learn how this gold-standard PXR agonist empowers advanced experimental designs, with actionable troubleshooting and best-practice insights for robust, reproducible results.

• HBTU in Peptide Bond Formation: Workflow, Performance & Tips

  2026-05-10

  HBTU (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) is a gold-standard peptide coupling reagent, enabling high-yield, racemization-resistant synthesis even for complex and enzyme-responsive peptides. This guide translates current research advances into practical workflows, protocol optimizations, and troubleshooting strategies for researchers seeking robust peptide bond formation.

• Applied Tofacitinib Citrate (CP-690550 citrate) in Immune Re

  2026-05-09

  Tofacitinib citrate (CP-690550 citrate) offers bench researchers nanomolar JAK3 inhibition for dissecting immune regulation and inflammatory disorder pathways. This guide translates cutting-edge comparative vascular safety data and hands-on protocol refinements into actionable workflows, troubleshooting, and optimization tips for reliable immune modulation studies.

• IGF2BP3–FZD1/7 Axis Drives Stemness and Chemoresistance in T

  2026-05-09

  This study identifies IGF2BP3 as a dominant m6A reader stabilizing FZD1/7 transcripts, thereby promoting cancer stem-like properties and carboplatin resistance in triple-negative breast cancer (TNBC). Targeting this axis may improve therapy efficacy by sensitizing TNBC stem cells to chemotherapy while reducing toxicity.

• Meropenem: Applied Workflows in β-Lactam Carbapenem Research

  2026-05-08

  Meropenem, an ultra-broad-spectrum β-lactam antibiotic carbapenem, enables robust modeling of Gram-negative and Gram-positive bacterial resistance in both basic and translational research. This guide details stepwise experimental enhancements, protocol-critical parameters, and troubleshooting strategies that maximize Meropenem’s reliability for resistance and septicemia studies.

16839 records 1/1123 page Next 12345 下5页 Last page